Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Papillomavirus Infections 2Neoplasms 2Liver Neoplasms 2Liver Diseases 2Virus Diseases 1Stomach Neoplasms 1Rheumatic Diseases 1Primary Graft Dysfunction 1Liver Failure, Acute 1Liver Failure 1Head and Neck Neoplasms 1HIV Infections 1Gastrointestinal Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Carcinoma, Squamous Cell 1Adenocarcinoma 1

Interventions

Oxaliplatin 295Capecitabine 209Fluorouracil 183Cisplatin 172Docetaxel 140S 1 (combination) 135Paclitaxel 128Leucovorin 117Irinotecan 110pembrolizumab 104Trastuzumab 75Nivolumab 59apatinib 57Drug Therapy 52sintilimab 46Surgical Procedures, Operative 45Ramucirumab 40Radiotherapy 40Bevacizumab 37Hyperthermic Intraperitoneal Chemotherapy 34Epirubicin 32titanium silicide 31tislelizumab 31Carboplatin 31Gastrectomy 28Cyclophosphamide 27XELOX 25Tegafur 24Folfox protocol 23Albumin-Bound Paclitaxel 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × halofantrine × Clear all
NCT02015169 2018-01-17

Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis

Samsung Medical Center

Phase 2 Completed
32 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡